Literature DB >> 23063513

A C-terminally amidated analogue of ShK is a potent and selective blocker of the voltage-gated potassium channel Kv1.3.

Michael W Pennington1, M Harunur Rashid, Rajeev B Tajhya, Christine Beeton, Serdar Kuyucak, Raymond S Norton.   

Abstract

ShK, a 35-residue peptide from a sea anemone, is a potent blocker of potassium channels. Here we describe a new ShK analogue with an additional C-terminus Lys residue and amide. ShK-K-amide is a potent blocker of Kv1.3 and, in contrast to ShK and ShK-amide, is selective for Kv1.3. To understand this selectivity, we created complexes of ShK-K-amide with Kv1.3 and Kv1.1 using docking and molecular dynamics simulations, then performed umbrella sampling simulations to construct the potential of mean force of the ligand and calculate the corresponding binding free energy for the most stable configuration. The results agree well with experimental data.
Copyright © 2012 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23063513      PMCID: PMC3496055          DOI: 10.1016/j.febslet.2012.09.038

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  27 in total

1.  The D-diastereomer of ShK toxin selectively blocks voltage-gated K+ channels and inhibits T lymphocyte proliferation.

Authors:  Christine Beeton; Brian J Smith; Jennifer K Sabo; George Crossley; Daniel Nugent; Ilya Khaytin; Victor Chi; K George Chandy; Michael W Pennington; Raymond S Norton
Journal:  J Biol Chem       Date:  2007-11-05       Impact factor: 5.157

2.  Engineering a stable and selective peptide blocker of the Kv1.3 channel in T lymphocytes.

Authors:  M W Pennington; C Beeton; C A Galea; B J Smith; V Chi; K P Monaghan; A Garcia; S Rangaraju; A Giuffrida; D Plank; G Crossley; D Nugent; I Khaytin; Y Lefievre; I Peshenko; C Dixon; S Chauhan; A Orzel; T Inoue; X Hu; R V Moore; R S Norton; K G Chandy
Journal:  Mol Pharmacol       Date:  2009-01-02       Impact factor: 4.436

Review 3.  Development of a sea anemone toxin as an immunomodulator for therapy of autoimmune diseases.

Authors:  Victor Chi; Michael W Pennington; Raymond S Norton; Eric J Tarcha; Luz M Londono; Brian Sims-Fahey; Sanjeev K Upadhyay; Jonathan T Lakey; Shawn Iadonato; Heike Wulff; Christine Beeton; K George Chandy
Journal:  Toxicon       Date:  2011-08-12       Impact factor: 3.033

Review 4.  Analogs of the sea anemone potassium channel blocker ShK for the treatment of autoimmune diseases.

Authors:  Christine Beeton; Michael W Pennington; Raymond S Norton
Journal:  Inflamm Allergy Drug Targets       Date:  2011-10

5.  Ionisation behaviour and solution properties of the potassium-channel blocker ShK toxin.

Authors:  J E Tudor; M W Pennington; R S Norton
Journal:  Eur J Biochem       Date:  1998-01-15

6.  An essential binding surface for ShK toxin interaction with rat brain potassium channels.

Authors:  M W Pennington; V M Mahnir; I Khaytin; I Zaydenberg; M E Byrnes; W R Kem
Journal:  Biochemistry       Date:  1996-12-24       Impact factor: 3.162

7.  Kv1.3 channels are a therapeutic target for T cell-mediated autoimmune diseases.

Authors:  Christine Beeton; Heike Wulff; Nathan E Standifer; Philippe Azam; Katherine M Mullen; Michael W Pennington; Aaron Kolski-Andreaco; Eric Wei; Alexandra Grino; Debra R Counts; Ping H Wang; Christine J LeeHealey; Brian S Andrews; Ananthakrishnan Sankaranarayanan; Daniel Homerick; Werner W Roeck; Jamshid Tehranzadeh; Kimber L Stanhope; Pavel Zimin; Peter J Havel; Stephen Griffey; Hans-Guenther Knaus; Gerald T Nepom; George A Gutman; Peter A Calabresi; K George Chandy
Journal:  Proc Natl Acad Sci U S A       Date:  2006-11-06       Impact factor: 11.205

8.  The voltage-gated Kv1.3 K(+) channel in effector memory T cells as new target for MS.

Authors:  Heike Wulff; Peter A Calabresi; Rameeza Allie; Sung Yun; Michael Pennington; Christine Beeton; K George Chandy
Journal:  J Clin Invest       Date:  2003-06       Impact factor: 14.808

9.  A novel fluorescent toxin to detect and investigate Kv1.3 channel up-regulation in chronically activated T lymphocytes.

Authors:  Christine Beeton; Heike Wulff; Satendra Singh; Steve Botsko; George Crossley; George A Gutman; Michael D Cahalan; Michael Pennington; K George Chandy
Journal:  J Biol Chem       Date:  2003-01-02       Impact factor: 5.157

10.  Pharmacological characterization of five cloned voltage-gated K+ channels, types Kv1.1, 1.2, 1.3, 1.5, and 3.1, stably expressed in mammalian cell lines.

Authors:  S Grissmer; A N Nguyen; J Aiyar; D C Hanson; R J Mather; G A Gutman; M J Karmilowicz; D D Auperin; K G Chandy
Journal:  Mol Pharmacol       Date:  1994-06       Impact factor: 4.436

View more
  24 in total

Review 1.  Computational approaches for designing potent and selective analogs of peptide toxins as novel therapeutics.

Authors:  Serdar Kuyucak; Raymond S Norton
Journal:  Future Med Chem       Date:  2014-10       Impact factor: 3.808

2.  Conformational flexibility in the binding surface of the potassium channel blocker ShK.

Authors:  Inbal Sher; Shih Chieh Chang; Ying Li; Sandeep Chhabra; Arthur G Palmer; Raymond S Norton; Jordan H Chill
Journal:  Chembiochem       Date:  2014-09-18       Impact factor: 3.164

3.  Prolonged immunomodulation in inflammatory arthritis using the selective Kv1.3 channel blocker HsTX1[R14A] and its PEGylated analog.

Authors:  Mark R Tanner; Rajeev B Tajhya; Redwan Huq; Elizabeth J Gehrmann; Kathia E Rodarte; Mustafa A Atik; Raymond S Norton; Michael W Pennington; Christine Beeton
Journal:  Clin Immunol       Date:  2017-04-04       Impact factor: 3.969

Review 4.  Domain structure and function of matrix metalloprotease 23 (MMP23): role in potassium channel trafficking.

Authors:  Charles A Galea; Hai M Nguyen; K George Chandy; Brian J Smith; Raymond S Norton
Journal:  Cell Mol Life Sci       Date:  2013-08-03       Impact factor: 9.261

5.  A potent and Kv1.3-selective analogue of the scorpion toxin HsTX1 as a potential therapeutic for autoimmune diseases.

Authors:  M Harunur Rashid; Redwan Huq; Mark R Tanner; Sandeep Chhabra; Keith K Khoo; Rosendo Estrada; Vikas Dhawan; Satendra Chauhan; Michael W Pennington; Christine Beeton; Serdar Kuyucak; Raymond S Norton
Journal:  Sci Rep       Date:  2014-03-28       Impact factor: 4.379

Review 6.  Immunosuppressive peptides and their therapeutic applications.

Authors:  Kathrin Thell; Roland Hellinger; Gernot Schabbauer; Christian W Gruber
Journal:  Drug Discov Today       Date:  2013-12-11       Impact factor: 7.851

7.  Molecular dynamics study of binding of µ-conotoxin GIIIA to the voltage-gated sodium channel Na(v)1.4.

Authors:  Somayeh Mahdavi; Serdar Kuyucak
Journal:  PLoS One       Date:  2014-08-18       Impact factor: 3.240

8.  Development of highly selective Kv1.3-blocking peptides based on the sea anemone peptide ShK.

Authors:  Michael W Pennington; Shih Chieh Chang; Satendra Chauhan; Redwan Huq; Rajeev B Tajhya; Sandeep Chhabra; Raymond S Norton; Christine Beeton
Journal:  Mar Drugs       Date:  2015-01-16       Impact factor: 5.118

Review 9.  Computational studies of marine toxins targeting ion channels.

Authors:  M Harunur Rashid; Somayeh Mahdavi; Serdar Kuyucak
Journal:  Mar Drugs       Date:  2013-03-13       Impact factor: 5.118

10.  A potent and selective peptide blocker of the Kv1.3 channel: prediction from free-energy simulations and experimental confirmation.

Authors:  M Harunur Rashid; Germano Heinzelmann; Redwan Huq; Rajeev B Tajhya; Shih Chieh Chang; Sandeep Chhabra; Michael W Pennington; Christine Beeton; Raymond S Norton; Serdar Kuyucak
Journal:  PLoS One       Date:  2013-11-07       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.